Guidance
Update information
December 2020: Recommendation 1.4 updated to clarify when upadacitinib can be used as monotherapy.
Minor changes since publication
January 2022: Link to NICE Pathway removed.
November 2021: We added a link to the technology appraisal guidance on upadacitinib for treating moderate rheumatoid arthritis.
ISBN: 978-1-4731-3937-4